GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » ROE %

SHC (Sotera Health Co) ROE % : 15.23% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sotera Health Co's annualized net income for the quarter that ended in Sep. 2024 was $68 Mil. Sotera Health Co's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $446 Mil. Therefore, Sotera Health Co's annualized ROE % for the quarter that ended in Sep. 2024 was 15.23%.

The historical rank and industry rank for Sotera Health Co's ROE % or its related term are showing as below:

SHC' s ROE % Range Over the Past 10 Years
Min: -49.89   Med: -0.15   Max: 22.51
Current: 16.5

During the past 6 years, Sotera Health Co's highest ROE % was 22.51%. The lowest was -49.89%. And the median was -0.15%.

SHC's ROE % is ranked better than
90% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.025 vs SHC: 16.50

Sotera Health Co ROE % Historical Data

The historical data trend for Sotera Health Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotera Health Co ROE % Chart

Sotera Health Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - - 22.51 -49.89 12.94

Sotera Health Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.73 37.68 5.79 8.22 15.23

Competitive Comparison of Sotera Health Co's ROE %

For the Diagnostics & Research subindustry, Sotera Health Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotera Health Co's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's ROE % distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's ROE % falls into.



Sotera Health Co ROE % Calculation

Sotera Health Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=51.376/( (350.238+443.734)/ 2 )
=51.376/396.986
=12.94 %

Sotera Health Co's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=67.992/( (422.764+470.163)/ 2 )
=67.992/446.4635
=15.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Sotera Health Co  (NAS:SHC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=67.992/446.4635
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(67.992 / 1141.872)*(1141.872 / 3103.2775)*(3103.2775 / 446.4635)
=Net Margin %*Asset Turnover*Equity Multiplier
=5.95 %*0.368*6.9508
=ROA %*Equity Multiplier
=2.19 %*6.9508
=15.23 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=67.992/446.4635
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (67.992 / 171.016) * (171.016 / 322.028) * (322.028 / 1141.872) * (1141.872 / 3103.2775) * (3103.2775 / 446.4635)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.3976 * 0.5311 * 28.2 % * 0.368 * 6.9508
=15.23 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sotera Health Co ROE % Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sotera Health Co Business Description

Traded in Other Exchanges
N/A
Address
9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Executives
Warburg Pincus & Co. director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp director, 10 percent owner 300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Ann R. Klee director 30 ISABELLA ST., PITTSBURGH PA 15212
Michael P Rutz officer: President of Sterigenics 8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Petras Michael B. Jr. director, officer: Chairman & CEO 9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Jonathan M. Lyons officer: Sr. Vice President, CFO 9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Robert Brown Knauss director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Alexander Dimitrief officer: SVP, General Counsel and Sec. GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl officer: Interim CFO 5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons officer: SVP, GC and Secretary C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Wp Xi Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Matthew J Klaben officer: SVP, GC and Secretary ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Stephanie Geveda director 450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654